Neurelis vs BioNTech
Side-by-side comparison of AI visibility scores, market position, and capabilities
Neuroscience pharma commercializing VALTOCO (diazepam nasal spray) for seizure clusters. ~$295-300M estimated net sales in 2025; 30%+ EBITDA margin; no bank debt.
About
Neurelis is a private neuroscience-focused pharmaceutical company dedicated to developing and commercializing therapies for epilepsy and neurological disorders. Its lead commercial product, VALTOCO (diazepam nasal spray), is an FDA-approved treatment for acute seizure clusters in patients aged two and older — a label expansion to children ages two to five was approved in April 2025. The company reported estimated net sales of $295–300 million for 2025, more than doubling 2024 revenue, with an EBITDA margin exceeding 30% and a debt-free balance sheet holding $175M+ in cash. VALTOCO''s Orange Book patent portfolio now includes six listed patents, extending exclusivity to October 2032. Neurelis is using this commercial momentum to advance its CNS pipeline and pursue additional products.
German mRNA pioneer co-developed COVID-19 vaccine with Pfizer; 20+ clinical programs in oncology and infectious disease;
About
BioNTech SE was founded in 2008 in Mainz, Germany by Ugur Sahin, Ozlem Tureci, and Christoph Huber with a mission to harness the immune system for individualized cancer treatment. The company pioneered individualized neoantigen-specific immunotherapy and mRNA-based therapeutic approaches before co-developing the world's first authorized mRNA vaccine with Pfizer during the COVID-19 pandemic.\n\nBioNTech's pipeline spans over 20 clinical programs in oncology, infectious disease, and autoimmune conditions. Key assets include BNT111, an mRNA cancer vaccine for melanoma evaluated in combination with Regeneron's cemiplimab, as well as a suite of CAR-T, bispecific antibody, and mRNA-encoded cytokine programs. The company manufactures mRNA therapies at scale through its BioNTainer modular facilities deployable to emerging markets.\n\nBioNTech generated approximately €2.4 billion in revenue in 2024 and holds a robust cash position exceeding €17 billion, enabling sustained R&D investment. The company is recognized as one of the most pivotal biotech success stories of the 21st century, combining deep immunology science with scalable mRNA manufacturing to pursue a world where cancer is a manageable disease.
Key Details
Capabilities & Ecosystem
Also Compare
Track AI Visibility in Real Time
Monitor how your brand performs across ChatGPT, Gemini, Perplexity, Claude, and Grok daily.